Literature DB >> 16478502

Propionibacterium acnes.

A L Perry1, P A Lambert.   

Abstract

Propionibacterium acnes, a common skin organism, is most notably recognized for its role in acne vulgaris. It also causes postoperative and device-related infections and has been associated with a number of other conditions such as sarcoidosis and synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), although its precise role as a causative agent remains to be determined. Propionibacterium acnes produces a number of virulence factors and is well known for its inflammatory and immunomodulatory properties. Recent publication of the P. acnes genome should provide further insights into the pathogenic capabilities of the organism and potentially lead to the development of new therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478502     DOI: 10.1111/j.1472-765X.2006.01866.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  34 in total

1.  Propionibacterium acnes delayed infection following spinal surgery with instrumentation.

Authors:  Hani H Mhaidli; Asdghig H Der-Boghossian; Rachid K Haidar
Journal:  Musculoskelet Surg       Date:  2012-03-23

2.  Complete genome sequence of Propionibacterium acnes type IB strain 6609.

Authors:  Judit Hunyadkürti; Zsófia Feltóti; Balázs Horváth; Marianna Nagymihály; Andrea Vörös; Andrew McDowell; Sheila Patrick; Edit Urbán; István Nagy
Journal:  J Bacteriol       Date:  2011-06-24       Impact factor: 3.490

3.  Propionibacterium acnes and Staphylococcus epidermidis isolated from refractory endodontic lesions are opportunistic pathogens.

Authors:  Sadia A Niazi; Douglas Clarke; Thuy Do; Steven C Gilbert; Francesco Mannocci; David Beighton
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

4.  Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris.

Authors:  Pei-Feng Liu; Teruaki Nakatsuji; Wenhong Zhu; Richard L Gallo; Chun-Ming Huang
Journal:  Vaccine       Date:  2011-02-26       Impact factor: 3.641

5.  Proteomics integrated with Escherichia coli vector-based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase-like protein of Propionibacterium acnes.

Authors:  Cheng-Po Huang; Yu-Tsueng Liu; Teruaki Nakatsuji; Yang Shi; Richard R Gallo; Shwu-Bin Lin; Chun-Ming Huang
Journal:  Proteomics Clin Appl       Date:  2008-07-24       Impact factor: 3.494

6.  Clinical significance of Propionibacterium acnes recovered from blood cultures: analysis of 524 episodes.

Authors:  Hyun Jung Park; Shin Na; Seong Yeon Park; Song Mi Moon; Oh-Hyun Cho; Ki-Ho Park; Yong Pil Chong; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Mi-Na Kim; Sang-Ho Choi
Journal:  J Clin Microbiol       Date:  2011-02-16       Impact factor: 5.948

Review 7.  Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment.

Authors:  Francesco Cianci; Angelo Zoli; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Clin Rheumatol       Date:  2017-07-19       Impact factor: 2.980

8.  A peptide with a ProGln C terminus in the human saliva peptidome exerts bactericidal activity against Propionibacterium acnes.

Authors:  Chun-Ming Huang; Justin W Torpey; Yu-Tseung Liu; Yun-Ru Chen; Katherine E Williams; Elizabeth A Komives; Richard L Gallo
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

9.  Diversity of bacterial endosymbionts associated with Macrosteles leafhoppers vectoring phytopathogenic phytoplasmas.

Authors:  Yoshiko Ishii; Yu Matsuura; Shigeyuki Kakizawa; Naruo Nikoh; Takema Fukatsu
Journal:  Appl Environ Microbiol       Date:  2013-06-14       Impact factor: 4.792

10.  Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study.

Authors:  Martina Kerscher; Tilmann Reuther; Julia Bayrhammer; Georg Schramm
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.